{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:48:01Z","timestamp":1772214481375,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,2,4]],"date-time":"2015-02-04T00:00:00Z","timestamp":1423008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s40265-015-0354-5","type":"journal-article","created":{"date-parts":[[2015,2,3]],"date-time":"2015-02-03T10:03:22Z","timestamp":1422957802000},"page":"407-418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Fluticasone Furoate\/Vilanterol: a Review of Its Use in Patients with Asthma"],"prefix":"10.1007","volume":"75","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,4]]},"reference":[{"key":"354_CR1","unstructured":"British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. 2008, revised January 2012. http:\/\/www.sign.ac.uk . Accessed 22 Dec 2014."},{"key":"354_CR2","unstructured":"European Medicines Agency. Relvar Ellipta (fluticasone furoate\/vilanterol): summary of product characteristics 2013. http:\/\/www.ema.europa.eu . Accessed 22 Dec 2014."},{"issue":"1","key":"354_CR3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1124\/mol.107.040121","volume":"73","author":"M Kaur","year":"2008","unstructured":"Kaur M, Chivers JE, Giembycz MA, et al. Long-acting \u03b22-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol. 2008;73(1):203\u201314.","journal-title":"Mol Pharmacol."},{"issue":"7","key":"354_CR4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.18553\/jmcp.2012.18.7.527","volume":"18","author":"CI Coleman","year":"2012","unstructured":"Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527\u201339.","journal-title":"J Manag Care Pharm."},{"key":"354_CR5","unstructured":"National Institute for Health and Care Excellence. ESNM34: Asthma: fluticasone furoate\/vilanterol (Relvar Ellipta) combination inhaler. 2014. http:\/\/www.nice.org.uk . Accessed 22 Dec 2014."},{"key":"354_CR6","unstructured":"GlaxoSmithKline, Theravance Inc. Relvar\u2122 Ellipta\u2122 gains approval in Japan for the treatment of asthma [media release]. 20 Sept 2013. http:\/\/www.gsk.com ."},{"key":"354_CR7","author":"K McKeage","year":"2014","unstructured":"McKeage K. Fluticasone furoate\/vilanterol: a review of tts use in chronic obstructive pulmonary disease. Drugs. 2014. doi: 10.1007\/s40265-014-0269-6 .","journal-title":"Drugs."},{"issue":"3","key":"354_CR8","doi-asserted-by":"crossref","first-page":"L660","DOI":"10.1152\/ajplung.00108.2007","volume":"293","author":"M Salter","year":"2007","unstructured":"Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L660\u20137.","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"issue":"12","key":"354_CR9","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1021\/jm800279t","volume":"51","author":"K Biggadike","year":"2008","unstructured":"Biggadike K, Bledsoe RK, Hassell AM, et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem. 2008;51(12):3349\u201352.","journal-title":"J Med Chem."},{"key":"354_CR10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1465-9921-8-54","volume":"8","author":"A Valotis","year":"2007","unstructured":"Valotis A, Hogger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8:54.","journal-title":"Respir Res."},{"issue":"1","key":"354_CR11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejphar.2011.08.022","volume":"670","author":"C Rossios","year":"2011","unstructured":"Rossios C, To Y, To M, et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol. 2011;670(1):244\u201351.","journal-title":"Eur J Pharmacol."},{"issue":"4","key":"354_CR12","doi-asserted-by":"crossref","first-page":"e93754","DOI":"10.1371\/journal.pone.0093754","volume":"9","author":"N Zhang","year":"2014","unstructured":"Zhang N, Van Crombruggen K, Holtappels G, et al. Suppression of cytokine release by fluticasone furoate vs. mometasone furoate in human nasal tissue ex-vivo. PLoS One. 2014;9(4):e93754.","journal-title":"PLoS One."},{"issue":"1","key":"354_CR13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/jpet.112.198481","volume":"344","author":"RJ Slack","year":"2013","unstructured":"Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting \u03b22-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013;344(1):218\u201330.","journal-title":"J Pharmacol Exp Ther."},{"issue":"3","key":"354_CR14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1183\/09031936.00121411","volume":"40","author":"J Lotvall","year":"2012","unstructured":"Lotvall J, Bateman ED, Bleecker ER, et al. 24-h duration of the novel LABA vilanterol trifenatate in asthma patients treated with inhaled corticosteroids. Eur Respir J. 2012;40(3):570\u20139.","journal-title":"Eur Respir J."},{"issue":"3","key":"354_CR15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1124\/pr.111.004580","volume":"64","author":"M Cazzola","year":"2012","unstructured":"Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450\u2013504.","journal-title":"Pharmacol Rev."},{"issue":"2","key":"354_CR16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.pupt.2012.12.001","volume":"26","author":"R Kempsford","year":"2013","unstructured":"Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013;26(2):256\u201364.","journal-title":"Pulm Pharmacol Ther."},{"issue":"1","key":"354_CR17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/thoraxjnl-2011-200308","volume":"67","author":"WW Busse","year":"2012","unstructured":"Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012;67(1):35\u201341.","journal-title":"Thorax."},{"issue":"8","key":"354_CR18","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.rmed.2012.03.007","volume":"106","author":"R Sterling","year":"2012","unstructured":"Sterling R, Lim J, Frith L, et al. Efficacy and optimal dosing interval of the long-acting beta2 agonist, vilanterol, in persistent asthma: a randomised trial. Respir Med. 2012;106(8):1110\u20135.","journal-title":"Respir Med."},{"issue":"5","key":"354_CR19","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.anai.2012.08.017","volume":"109","author":"ER Bleecker","year":"2012","unstructured":"Bleecker ER, Bateman ED, Busse WW, et al. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann Allergy Asthma Immunol. 2012;109(5):353\u2013358.e4.","journal-title":"Ann Allergy Asthma Immunol."},{"issue":"5","key":"354_CR20","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.rmed.2012.01.004","volume":"106","author":"ED Bateman","year":"2012","unstructured":"Bateman ED, Bleecker ER, Lotvall J, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med. 2012;106(5):642\u201350.","journal-title":"Respir Med."},{"key":"354_CR21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1465-9921-12-160","volume":"12","author":"A Woodcock","year":"2011","unstructured":"Woodcock A, Bleecker ER, Busse WW, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res. 2011;12:160.","journal-title":"Respir Res."},{"issue":"12","key":"354_CR22","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.rmed.2013.07.002","volume":"107","author":"RD Kempsford","year":"2013","unstructured":"Kempsford RD, Oliver A, Bal J, et al. The efficacy of once-daily fluticasone furoate\/vilanterol in asthma is comparable with morning or evening dosing. Respir Med. 2013;107(12):1873\u201380.","journal-title":"Respir Med."},{"issue":"9","key":"354_CR23","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/all.12205","volume":"68","author":"A Oliver","year":"2013","unstructured":"Oliver A, Bjermer L, Quinn D, et al. Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy. 2013;68(9):1136\u201342.","journal-title":"Allergy."},{"issue":"1","key":"354_CR24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2045-7022-2-11","volume":"2","author":"A Oliver","year":"2012","unstructured":"Oliver A, Quinn D, Goldfrad C, et al. Combined fluticasone furoate\/vilanterol reduces decline in lung function following inhaled allergen 23\u00a0h after dosing in adult asthma: a randomised, controlled trial. Clin Transl Allergy. 2012;2(1):11.","journal-title":"Clin Transl Allergy."},{"issue":"3","key":"354_CR25","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bcp.12243","volume":"77","author":"R Kempsford","year":"2014","unstructured":"Kempsford R, Allen A, Kelly K, et al. A repeat-dose thorough QT study of inhaled fluticasone furoate\/vilanterol combination in healthy subjects. Br J Clin Pharmacol. 2014;77(3):466\u201379.","journal-title":"Br J Clin Pharmacol."},{"key":"354_CR26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40262-012-0021-x","volume":"52","author":"A Allen","year":"2013","unstructured":"Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013;52:37\u201342.","journal-title":"Clin Pharmacokinet."},{"issue":"11","key":"354_CR27","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1124\/dmd.108.022137","volume":"36","author":"SC Hughes","year":"2008","unstructured":"Hughes SC, Shardlow PC, Hollis FJ, et al. Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. Drug Metab Dispos. 2008;36(11):2337\u201344.","journal-title":"Drug Metab Dispos."},{"issue":"1","key":"354_CR28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1124\/dmd.112.048603","volume":"41","author":"AW Harrell","year":"2013","unstructured":"Harrell AW, Siederer SK, Bal J, et al. Metabolism and disposition of vilanterol, a long-acting \u03b22-adrenoceptor agonist for inhalation use in humans. Drug Metab Dispos. 2013;41(1):89\u2013100.","journal-title":"Drug Metab Dispos."},{"issue":"6","key":"354_CR29","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/bcp.12019","volume":"75","author":"R Kempsford","year":"2012","unstructured":"Kempsford R, Allen A, Bal J. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects. Br J Clin Pharmacol. 2012;75(6):1478\u201387.","journal-title":"Br J Clin Pharmacol."},{"issue":"12","key":"354_CR30","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.clinthera.2012.11.001","volume":"34","author":"A Allen","year":"2012","unstructured":"Allen A, Davis A, Hardes K, et al. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination. Clin Ther. 2012;34(12):2316\u201332.","journal-title":"Clin Ther."},{"issue":"5","key":"354_CR31","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bcp.12263","volume":"77","author":"A Allen","year":"2014","unstructured":"Allen A, Bal J, Cheesbrough A, et al. Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. Br J Clin Pharmacol. 2014;77(5):808\u201320.","journal-title":"Br J Clin Pharmacol."},{"key":"354_CR32","author":"ER Bleecker","year":"2014","unstructured":"Bleecker ER, L\u00f6tvall J, O\u2019Byrne PM, et al. Fluticasone furoate\u2013vilanterol 100\u201325\u00a0mcg compared with fluticasone furoate 100\u00a0mcg in asthma: a randomized trial. J Allergy Clin Immunol Pract. 2014. doi: 10.1016\/j.jaip.2014.02.010 .","journal-title":"J Allergy Clin Immunol Pract."},{"key":"354_CR33","unstructured":"GlaxoSmithKline. GSK clinical study register. 2013. http:\/\/www.gsk-clinicalstudyregister.com . Accessed 22 Dec 2014."},{"issue":"4","key":"354_CR34","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1378\/chest.13-0178","volume":"144","author":"A Woodcock","year":"2013","unstructured":"Woodcock A, Bleecker ER, Lotvall J, et al. Efficacy and safety of fluticasone furoate\/vilanterol compared with fluticasone propionate\/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest. 2013;144(4):1222\u20139.","journal-title":"Chest."},{"issue":"3","key":"354_CR35","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1183\/09031936.00064513","volume":"43","author":"PM O\u2019Byrne","year":"2014","unstructured":"O\u2019Byrne PM, Bleecker ER, Bateman ED, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J. 2014;43(3):773\u201382.","journal-title":"Eur Respir J."},{"issue":"4","key":"354_CR36","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/thoraxjnl-2013-203600","volume":"69","author":"ED Bateman","year":"2014","unstructured":"Bateman ED, O\u2019Byrne PM, Busse WW, et al. Once-daily fluticasone furoate (FF)\/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014;69(4):312\u20139.","journal-title":"Thorax."},{"key":"354_CR37","unstructured":"US National Institutes of Health. ClinicalTrials.gov. 2012. http:\/\/clinicaltrials.gov . Accessed 22 Dec 2014."},{"issue":"6","key":"354_CR38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1136\/thoraxjnl-2012-202606","volume":"68","author":"WW Busse","year":"2013","unstructured":"Busse WW, O\u2019Byrne PM, Bleecker ER, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the \u03b22 agonist vilanterol administered once daily for 52\u00a0weeks in patients\u00a0\u226512\u00a0years old with asthma: a randomised trial. Thorax. 2013;68(6):513\u201320.","journal-title":"Thorax."},{"issue":"4","key":"354_CR39","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/crj.12026","volume":"7","author":"A Allen","year":"2013","unstructured":"Allen A, Schenkenberger I, Trivedi R, et al. Inhaled fluticasone furoate\/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study. Clin Respir J. 2013;7(4):397\u2013406.","journal-title":"Clin Respir J."},{"key":"354_CR40","unstructured":"GlaxoSmithKline. GSK and Theravance announce submission to US regulatory authorities for fluticasone furoate\/vilanterol in asthma [media release]. 30 June 2014. http:\/\/us.gsk.com\/ ."},{"key":"354_CR41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2466-13-72","volume":"13","author":"H Svedsater","year":"2013","unstructured":"Svedsater H, Dale P, Garrill K, et al. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013;13:72.","journal-title":"BMC Pulm Med."},{"key":"354_CR42","author":"JP New","year":"2014","unstructured":"New JP, Bakerly ND, Leather D, et al. Obtaining real-world evidence: the Salford Lung Study. Thorax. 2014. doi: 10.1136\/thoraxjnl-2014-205259 .","journal-title":"Thorax."},{"key":"354_CR43","unstructured":"GlaxoSmithKline. Breo Ellipta (fluticasone furoate and vilanterol inhalation powder): US prescribing information. 2014. http:\/\/www.fda.gov . Accessed 22 Dec 2014."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0354-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0354-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0354-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T09:50:36Z","timestamp":1651139436000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0354-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["354"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0354-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,4]]}}}